Northway Biotech Launches Full-Service Viral Clearance Studies, Delivering Results Faster Than Industry Standards

VILNIUS, LT, May 5, 2025 – Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), has announced the expansion of its services in protein-based and gene therapy by introducing capabilities for Viral Clearance Studies (VCS). This strategic development comes after the establishment of the new Gene Therapy Center by Northway Biotech, equipped with specialized cGMP facilities for virus-related projects.

The company now has six identical BSL-2 laboratories in operation, enabling them to carry out VCS programs for up to six clients concurrently, which will help address current market challenges. Moreover, Northway Biotech has enhanced its capacity to undertake GMP-compliant manufacturing and testing under BSL-3 conditions, enhancing its services in gene therapy and other biologics development.

Viral Clearance Studies are now available both as a part of Northway Biotech’s comprehensive CDMO programs and as a separate service. This flexibility allows external clients to access VCS expertise independently, without the need for a manufacturing agreement.

The company is now capable of completing Viral Clearance Studies faster than the industry standard, leveraging its expanded infrastructure and integrated analytical capabilities. These studies, which evaluate viral removal and inactivation, can now be finalized with regulatory-compliant reporting in less than 10 weeks when utilizing two model viruses, and within 12 weeks with four model viruses.

Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, expressed that the expansion into Viral Clearance Studies is a natural progression of their services, enabling them to handle these crucial studies in-house and significantly reduce project durations for clients. By investing in advanced BSL-2 and BSL-3 facilities, enhancing technical capabilities, and strengthening scientific teams, Northway Biotech is in a unique position to deliver high-quality VCS data promptly, giving clients a competitive advantage in clinical development and regulatory approval.

For more information on Northway Biotech’s Viral Clearance Study processes, service offerings, and delivery timelines, interested parties can connect with the Northway Biotech team through the contact form on their website.

About Northway Biotech – Northway Biotech is a reputable contract development and manufacturing organization (CDMO) that provides support to clients globally. The company’s experienced team manages projects at all stages, from cell line construction to cGMP manufacturing of biopharmaceutical products. Operating since 2004, Northway Biotech has facilities in Vilnius, Lithuania; London, United Kingdom; and Waltham, MA, USA.

Contact Information:
bd@northwaybiotech.com
Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com

Source: Northway Biotech
Topic: Press release summary
Source: Northway Biotech
Sectors: BioTech, Healthcare & Pharma